- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Pfizer Launches Epoetin Alfa Biosimilar, Retacrit, at 33.5% Discount to Reference Epogen
Pfizer announced today that it has launched its epoetin alfa biosimilar, Retacrit, at a substantial discount to the reference product, Epogen.
Pfizer announced today that it has launched its epoetin alfa biosimilar, Retacrit, at a substantial discount to the reference product, Epogen.
Retacrit, which was approved in the European Union in 2007, just recently received FDA approval in May 2018 for all indications of the reference product as an erythropoiesis-stimulating agent. As of Monday, November 12, 2018, Pfizer announced the first shipment of the biosimilar had been sent to wholesalers in the US.
Retacrit will enter the US market at a wholesale acquisition cost (WAC) of $11.03 per 1000 units/mL, which is a 33.5% discount to the WAC of the reference product and a 57.1% discount to the WAC of Procrit.
The introduction of Retacrit into the US market brings the total number of available biosimilars to 6, while 14 are FDA-approved and delayed in entry due to patent litigation. For Pfizer specifically, this market launch marks their third biosimilar available.
“We are delighted to introduce our third biosimilar in the United States,” said John P. Kennedy, general manager, US Biosimilars, Pfizer Essential Health. “Pfizer is committed to fostering a sustainable marketplace for biosimilars and advocates for policies that bring these important medicines to patients and physicians as quickly as possible.”
Overcoming Challenges to Improve Access and Reduce Costs
November 12th 2024Biosimilars hold the potential to dramatically lower health care costs and improve access to life-changing treatments, but realizing this potential will require urgent policy reforms, market competition, and better education for both providers and patients.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Skyrizi Overtakes Humira: “Product Hopping” Leaves Biosimilar Market in Limbo
November 7th 2024For the first time, Skyrizi (risankizumab-rzaa) has replaced Humira (reference adalimumab) as AbbVie’s sales driver, largely due to companies encouraging “product hopping” to avoid competition, creating concerns for the sustainability of the burgeoning adalimumab biosimilar market.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Panelists Stress Stakeholder Education to Build Confidence in Biosimilars
October 31st 2024By expanding educational initiatives to clarify biosimilar safety, efficacy, and interchangeability, stakeholders can foster trust, improve access, and ensure that biosimilars are widely accepted as high-quality, cost-effective alternatives to originator biologics.
